Ioannis Tarnanas’ research focuses on using new technologies to understand the aging process and to establish prevention methods that decrease the risk of developing dementia or delay the onset of the disease. Tarnanas has developed models and screens of dementia using computerized tests of complex, real-life activities, such as a novel assessment of spatial navigation and movement trajectory. With this technology, Tarnanas recently created an accurate predictive tool based on cognitive and non-cognitive biomarkers of early onset dementia. The program—named Altoida AR—can spot the first neurological effects of Alzheimer’s disease with 94% accuracy up to six years before symptoms appear.
At GBHI, Tarnanas will continue to pursue his development of computational biomarkers of Alzheimer’s disease. He will also work with local and international Alzheimer advocacy organizations to develop a responsible strategy to implement this technology and utilize machine intelligence for disease prevention.
Bio: Ioannis Tarnanas is a neuroscientist, currently working as a senior research associate at the ETH Zurich Health Information Systems—a joint initiative that combines technology and behavioral sciences in the healthcare sector. He received a PhD in neuroscience from Aristotle University of Thessaloniki in Greece.